ArticleNature immunology2005
Function of NKG2D in natural killer cell-mediated rejection of mouse bone marrow grafts.
Article in Nature immunology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 170 citations in OpenAlex.
- NKG2D receptor ligands are cell surface biomarkers for injured murine and human nociceptive sensory neurons.Journal of neuroinflammation · 2025Article
- Natural killer cells in cancer immunotherapy.MedComm · 2024Review
- Donor NKG2D rs1049174 polymorphism predicts hematopoietic recovery and event-free survival after single-unit cord blood transplantation in adults.Bone marrow transplantation · 2024Article
- The Role of NKG2D and Its Ligands in Autoimmune Diseases: New Targets for Immunotherapy.International journal of molecular sciences · 2023Review
- NKG2D discriminates diverse ligands through selectively mechano-regulated ligand conformational changes.The EMBO journal · 2022Article
- Modified dendritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutation.Experimental hematology & oncology · 2022Article
- The natural killer cell activating receptor, NKG2D, is critical to antibody-dependent chronic rejection in heart transplantation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2021Article
- NKG2D Natural Killer Cell Receptor-A Short Description and Potential Clinical Applications.Cells · 2021Review
- Clonal expansion of innate and adaptive lymphocytes.Nature reviews. Immunology · 2020Review
- Regulation of murine NK cell exhaustion through the activation of the DNA damage repair pathway.JCI insight · 2019Article
- NK cell recognition of hematopoietic cells by SLAM-SAP families.Cellular & molecular immunology · 2019Review
- More than Decoration: Roles for Natural Killer Group 2 Member D Ligand Expression by Immune Cells.Frontiers in immunology · 2018Review
- Natural Killer Cells: Development, Maturation, and Clinical Utilization.Frontiers in immunology · 2018Review
- Working in "NK Mode": Natural Killer Group 2 Member D and Natural Cytotoxicity Receptors in Stress-Surveillance by γδ T Cells.Frontiers in immunology · 2018Review
- The NKG2D/NKG2DL Axis in the Crosstalk Between Lymphoid and Myeloid Cells in Health and Disease.Frontiers in immunology · 2018Review
- NKG2D and Its Ligands: "One for All, All for One".Frontiers in immunology · 2018Review
- NKG2D: A Master Regulator of Immune Cell Responsiveness.Frontiers in immunology · 2018Review
- Anti-NKG2D mAb: A New Treatment for Crohn's Disease?International journal of molecular sciences · 2017Review
- Chronic In Vivo Interaction of Dendritic Cells Expressing the Ligand Rae-1ε with NK Cells Impacts NKG2D Expression and Function.ImmunoHorizons · 2017Article
- The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy.Frontiers in immunology · 2017Review
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
Irradiation-resistant natural killer (NK) cells in an F(1) recipient can reject parental bone marrow, and host NK cells can also prevent engraftment of allogeneic bone marrow. We show here that repopulating bone marrow cells in certain mouse strains expressed retinoic acid early inducible 1 proteins, which are ligands for the activating NKG2D NK cell receptor. Treatment with a neutralizing antibody to NKG2D prevented rejection of parental BALB/c bone marrow in (C57BL/6 x BALB/c) F(1) recipients and allowed engraftment of allogeneic BALB.B bone marrow in C57BL/6 recipients. Additionally, bone marrow from C57BL/6 mice transgenic for retinoic acid early inducible 1epsilon was rejected by syngeneic mice but was accepted after treatment with antibody to NKG2D. If other stem cells or tissues upregulate expression of NKG2D ligands after transplantation, NKG2D may contribute to graft rejection in immunocompetent hosts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.